ResMed (RMD) Stock
Key stats
- Market cap
- $33.55B
- Price / Earnings ratio
- 20.7x
- EPS (TTM)
- $11.01
- Volume
- Loading
- 52-week high
- $277.67
- 52-week low
- $180.27
- Dividend yield
- 1.03%
- Dividend amount (latest)
- $0.66
- EPS vs analyst estimate
- +2.0%Q1 FY26 · $2.55 vs $2.50
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with RMD
Recent news

ResMed: 3 Key Takeaways for Long-Term Investors
ResMed: 3 Key Takeaways for Long-Term Investors
RMD

ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
RMD

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
RMD

What ResMed (RMD) Said on Its Q1 Earnings Call
What ResMed (RMD) Said on Its Q1 Earnings Call
RMD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.47
- MACD 12/26/9
- 0.85
- EMA 9 of MACD
- 2.31
- MACD histogram
- -1.47
- SMA 50
- $231.79
- Price above SMA 50
- EMA 50
- $233.12
- Price above EMA 50
- SMA 200
- $224.05
- Price above SMA 200
- EMA 200
- $230.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $2.80 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

ResMed: 3 Key Takeaways for Long-Term Investors
ResMed: 3 Key Takeaways for Long-Term Investors
RMD

ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
RMD

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
RMD

What ResMed (RMD) Said on Its Q1 Earnings Call
What ResMed (RMD) Said on Its Q1 Earnings Call
RMD

ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
RMD

Here's Why ResMed (RMD) is a Strong Growth Stock
Here's Why ResMed (RMD) is a Strong Growth Stock
RMD

Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
RMD

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
RMD

Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
RMD

ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
RMD
News tone: automated (AI) classification of the article's content, not a price prediction.
About ResMed
Resmed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Their digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. By enabling better care, they improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 1972 |
| Mr. Aaron Bloomer | Chief Financial Officer | 1986 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 1942 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 1958 |
| Mr. Brett A. Sandercock | Advisor | 1967 |
| Mr. Justin Leong | Chief Product Officer | 1978 |
| Mr. Alastair Robertson | Chief Information Officer | — |
| Mr. Jim Ellis | Chief Compliance Officer | — |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 1976 |
| Ms. Vered Keisar | Chief People Officer | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.47
- MACD 12/26/9
- 0.85
- EMA 9 of MACD
- 2.31
- MACD histogram
- -1.47
- SMA 50
- $231.79
- Price above SMA 50
- EMA 50
- $233.12
- Price above EMA 50
- SMA 200
- $224.05
- Price above SMA 200
- EMA 200
- $230.36
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $230.00
- Average
- $263.00
- High
- $288.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.9 | +2.8 | ||||||||||
| 2022 | -11.9 | +6.3 | -3.4 | -18.9 | +1.8 | +3.4 | +11.5 | -8.1 | -0.5 | -0.2 | +4.2 | -9.2 |
| 2023 | +9.2 | -7.0 | +2.3 | +9.9 | -10.1 | -0.1 | +3.6 | -29.2 | -7.1 | -3.1 | +7.2 | +7.8 |
| 2024 | +10.7 | -10.3 | +13.4 | +13.0 | -4.0 | -7.7 | +14.1 | +14.2 | -0.3 | +1.6 | +1.9 | -6.6 |
| 2025 | +3.4 | -2.9 | -4.0 | +6.4 | +3.5 | +5.7 | +6.1 | -1.7 | +1.0 | -8.8 | +2.8 | -3.0 |
| 2026 | +5.5 | +0.6 | -12.8 | -4.1 | -7.0 | +4.5 | +4.9 | +11.6 | -4.4 | +4.0 | +2.4 |



